Meredith W. Cook - 12 Feb 2026 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Role
SR. VP, GENERAL COUNSEL & SEC.
Signature
/s/ Meredith W. Cook
Issuer symbol
ANIP
Transactions as of
12 Feb 2026
Net transactions value
-$293,681
Form type
4
Filing time
17 Feb 2026, 16:04:20 UTC
Previous filing
13 Feb 2026
Next filing
02 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cook Meredith SR. VP, GENERAL COUNSEL & SEC. C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE /s/ Meredith W. Cook 17 Feb 2026 0001938861

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIP Common Stock Tax liability $117,658 -1,534 -2.1% $76.70 69,829 12 Feb 2026 Direct F1
transaction ANIP Common Stock Sale $38,400 -500 -0.72% $76.80 69,329 13 Feb 2026 Direct F2
transaction ANIP Common Stock Tax liability $137,623 -1,779 -2.6% $77.36 67,550 14 Feb 2026 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,243 shares of restricted stock, the grant of which was previously reported on February 18, 2025.
F2 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F3 Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,691 shares of restricted stock, the grant of which was previously reported on February 16, 2024.